Table 1: Summary of results from mouse models of OA.
Publication | Mouse Model | Pulmonary Function | Immune Response | Adipokines | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First Author | Year | Sex | Strain | Asthma | Diet Induced Obesity | AHR | AR | T cells | Cytokines | Eos | Neu | MΦ | Leptin | Adiponectin |
Lee [89] | 2019 | F | C57BL/6 |
A) OVA B) 25μg s.c. (2x) C) 20μg/50μl i.n. (4x) |
D) Harlan Laboratories E) D12492 F) 60% G) 12 |
↑ | ↑ | -- | Lung: ↑ IL-17 BALF: ↑ IL-4/5/13/17; ↓IFNγ Serum: ↑ IL-17 |
Lung: ↑1
BALF: ↑ |
Lung: ↑1 BALF: ↑ |
BALF: ↑ | BALF: ↑ Serum: ↑ |
BALF: → Serum: → |
→ | → | -- | Lung: → IL-17 BALF: →IL-4/13/17; ↓IFNγ; ↑ IL-5 Serum: ↑ IL-17 |
Lung: →1 BALF: → |
Lung: →1 BALF: → |
BALF: → | BALF: ↑ Serum: ↑ |
BALF: → Serum: → |
||||||
-- | -- | -- | -- | -- | -- | -- | -- | -- | ||||||
Schröder [90] | 2019 | F | C57BL/6JRj |
A) OVA B) 150μg/1mg i.p. (2x) C) 1.5% i.t.(4x) |
D) Ssniff EF R/M E) TD88137 F) 42% G) 12 |
↑ | ↑ | Lung: ↑ CD4+ BALF: ↑ T cells |
BALF: ↑ | BALF: ↑ | BALF: → | -- | -- | |
↓ | → | Lung: → CD4+ BALF: ↓ T cells |
BALF: → | BALF: ↓ | BALF: → | -- | -- | |||||||
↑ | ↑ | Lung: ↑ CD4+ BALF: → T cells |
BALF: ↑ | BALF: ↑ | BALF: → | -- | -- | |||||||
Zeng [91] | 2019 | M | C57BL/6 |
A) OVA B) 10μg i.p. (2x) C) 1 mg/mL aerosol (30 min daily × 7d) |
D) MediScience Ltd. E) MD12032 F) 45% G) 16 |
↑ | ↑ | Lung: ↑ Th17 | Lung1: ↑ IL17A, RORγt Serum: ↑IL-1β/6/17A |
-- | -- | -- | -- | -- |
↑ | ↑ | Lung: → Th17 | Lung1: → IL17A, RORγt Serum: ↑IL-1β/6/17A |
-- | -- | -- | -- | -- | ||||||
↑ | ↑ | Lung: → Th17 | Lung1: → IL17A, RORγt Serum: ↑IL-1β/6/17A |
-- | -- | -- | -- | -- | ||||||
*Chong [92] | 2018 | M/F | C57BL/6J |
A) OVA B) 0.01% OVA i.p. C) 1% OVA aerosol (30 min daily × 8d) |
D) MediScience Ltd. E) MD12032 F) 45% G) 12 |
↑ | ↑ | -- | -- | BALF: ↑ | BALF: ↑ | -- | -- | -- |
↑ | ↑ | -- | -- | -- | -- | -- | -- | -- | ||||||
↑ | ↑ | -- | -- | BALF: ↑ | BALF: ↓ | -- | -- | -- | ||||||
Liang [93] | 2018 | F | C57BL/6 |
A) OVA B) 25μg i.p. (2x) C) 20μg/50μL i.n. (3x) |
D) Harlan Laboratories E) D12492 F) 60% G) 12 |
↑ | ↑ | -- | BALF: ↑ IL-4/5/13/17 | BALF: ↑ | BALF: → | BALF: ↑ | Serum: ↑ | Serum: ↓ |
↑ | → | -- | BALF: ↑ IL-4/5/17; → IL-13 | BALF: ↑ | BALF: → | BALF: ↑ | Serum: ↑ | Serum: ↓ | ||||||
→ | ↑ | -- | BALF: ↑ IL-4/5/13/17 | BALF: ↑ | BALF: → | BALF: ↑ | Serum: ↑ | Serum: ↑ | ||||||
Zeng [94] | 2018 | M | C57BL/6 |
A) OVA B) 10μg i.p. (2x) C) 1 mg/mL aerosol (30 min daily × 7d) |
D) MediScience Ltd. E) MD12032 F) 45% G) 16 |
↑ | ↑ | Spleen: ↑Th17 | Lung1: ↑IL-17A Serum: ↑IL-17 |
-- | -- | -- | -- | -- |
↑ | ↑ | Spleen: ↑Th17 | Lung1: ↑IL-17A Serum: ↑IL-17 |
-- | -- | -- | -- | -- | ||||||
↑ | ↑ | Spleen: ↑Th17 | Lung1: ↑IL-17A Serum: ↑IL-17 |
-- | -- | -- | -- | -- | ||||||
*Everaere [101] | 2016 | -- | C57BL/6J |
A) HDM B) 5 IR i.n. (1x) C) 5 IR i.n. (5x) |
D) Research Diet Inc. E) D12492 F) 60% G) 12 |
↑ | ↑ | Lung: ↑ CD4+, IL13+CD4+, IL-17A+CD4+ | Lung2: ↑IL-1β/4/13/17A/23/33 VAT2: → IL-1β/17A, IFNγ; ↓IL-5/33 |
BALF: ↑ | BALF: → | BALF: → | -- | -- |
↑ | ↑ | Lung: ↑ CD4+, IL13+CD4+, IL-17A+CD4+ | Lung2: ↑IL-1β/4/13/17A/23/33 VAT2: → IL-1β/17A, IFNγ; ↓IL-5/33 |
BALF: ↑ | BALF: → | BALF: → | -- | -- | ||||||
↑ | ↑ | Lung: → CD4+, IL13+CD4+, IL-17A+CD4+ | Lung2: ↑IL-4/13/17A/33; → IL-1β/23 VAT2: → IL-1β/17A, IFNγ; ↓IL-5/33 |
BALF: ↑ | BALF: → | BALF: → | -- | -- | ||||||
Chen [95] | 2015 | -- | BALB/c |
A) OVA B) 25μg i.p. (3x) C) 6% (w/v) aerosol (daily × duration of diet > 12 weeks) |
D) Research Diet Inc. E) D12451 F) 45% G) 12 |
↑ | ↑ | -- | Serum: ↑IL-4; ↓IFNg | Lung: ↑ | -- | -- | -- | -- |
↑ | ↑ | -- | Serum: →IL-4; ↓IFNg | Lung: ↑ | -- | -- | -- | -- | ||||||
↑ | ↑ | -- | Serum: ↓IL-4; IFNg | Lung: ↑ | -- | -- | -- | -- | ||||||
Kim [96] | 2015 | F | C57BL/6 |
A) OVA B) 100μg i.p. (2x) C) 10μg i.n. (3x) |
D) Research Diet Inc. E) D12492 F) 60% G) 16 |
↑ | ↑ | -- | BALF: ↑ TNFα Serum: ↑ TNFα |
BALF: ↑ | BALF: ↑ | -- | Lung: → Serum: → |
Lung: → Serum: → |
↑ | → | -- | Lung: ↑ TNFα BALF: ↑ TNFα Serum: ↑ TNFα |
BALF: → | BALF: → | -- | -- | -- | ||||||
↑ | ↑ | -- | BALF: ↑ TNFα Serum: ↑ TNFα |
BALF: ↑ | BALF: ↑ | -- | -- | -- | ||||||
Jung [98] | 2013 | F | C57BL/6J |
A) OVA B) 25μg s.c. (5x) C) 20μg/50μL i.n. days 27, 29, 31 and then twice a week until week 18 |
D) Feedlab E) -- F) 45% G) 16 |
↑ | ↑ | -- | Lung2: ↑ VEGF, TNFα, TGFβ BALF: ↑ VEGF, TNFα, TGFβ |
BALF: ↑ | BALF: ↑ | BALF: ↑ | Lung: ↑ | Lung: ↓ |
↓ | ↑ | -- | Lung2: → VEGF, TGFβ; ↑ TNFα BALF: ↑ TNFα; → VEGF; ↓ TGFβ |
BALF: ↑ | BALF: → | BALF: → | Lung: ↑ | Lung: ↓ | ||||||
↑ | ↑ | -- | Lung2: → VEGF, TGFβ, ↑ TNFα BALF: ↑TNFα; →VEGF; ↓TGFβ |
BALF: ↑ | BALF: ↑ | BALF: ↑ | Lung: ↓ | Lung: ↑ | ||||||
Ryu [99] | 2013 | F | C57BL/6J |
A) OVA B) 25μg s.c. (5x) C) 20μg/50μL i.n. days 27, 29, 31 and then twice a week until week 18 |
D) Feedlab E) -- F) 45% G) 16 |
↑ | -- | -- | Lung2: ↑ VEGF, TNFα, TGFβ BALF: ↑ VEGF, TGFβ |
BALF: ↑ | BALF: ↑ | BALF: ↑ | Lung2: ↑ | Lung2: → |
↓ | -- | -- | Lung2: ↑ VEGF, TNFα, TGFβ BALF: ↑ TGFβ; → VEGF |
BALF: → | BALF: → | BALF: → | Lung2: → | Lung2: → | ||||||
↓ | -- | -- | Lung2: ↑ TNFα, TGFβ; ↓ VEGF BALF: ↓TGFβ, VEGF |
BALF: ↑ | BALF: → | BALF: ↑ | Lung2: → | Lung2: → | ||||||
Ge [97] | 2013 | M | C57BL/6J |
A) CRA B) 10μg s.c. + 10μg i.p (1x), 1μg s.c. (1x) (2x) C) 1μg i.n. (1x) then 4μg i.n. (1x) |
D) Bio-Serv E) F3282 E) 60% F) 16 |
↑ | ↑ | -- | Lung: ↑ IL-5, → IFNγ, IL-2/4/13, ↓ TNFα, | Lung: ↑ BALF: ↓ |
BALF: ↓ | BALF: ↑ | -- | -- |
↑ | ↓ | -- | Lung: → IL-4; ↓ IFNγ, TNFα, IL-2/5/13 | Lung: ↓ BALF: ↓ |
BALF: ↓ | BALF: ↑ | -- | -- | ||||||
↑ | ↑ | -- | Lung: ↑ IL-5; → IFNγ, TNFα, IL-2/4/13 | Lung: ↑ BALF: ↑ |
BALF: ↑ | BALF: ↑ | -- | -- |
Table Legend |
Obese Asthma vs Healthy Control |
Obese Asthma vs Asthma Alone |
Obese Asthma vs Obesity Alone |